MedicineNews.net - Medical Updates

Tymlos for the treatment of postmenopausal women with osteoporosis at high risk for fracture

The FDA ( US Food and Drug Administration ) has approved Tymlos ( Abaloparatide ) injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of ... read article

HER2-positive breast cancer: Neratinib, little benefit and severe toxicity

The FDA ( U.S. Food and Drug Administration ) has approved 1 year of extended adjuvant Neratinib ( Nerlynx ) after chemotherapy and a year of Trastuzumab ( Herceptin ) for HER2-positive breast cancer ... read article

KEYNOTE-061, Pembrolizumab does not meet primary endpoint of overall survival in previously treated patients with gastric or gastroesophageal junction adenocarcinoma

The pivotal phase 3 KEYNOTE-061 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a second-line treatment for patients with advanced gastric or gastroesophageal junction ( GEJ ) ... read article

Mvasi, a biosimilar to the cancer drug Avastin, approved from FDA for certain colorectal, lung, brain, kidney and cervical cancers

The FDA ( Food and Drug Administration ) has approved Mvasi ( Bevacizumab-awwb ) as a biosimilar to Avastin ( Bevacizumab ) for the treatment of multiple types of cancer. Mvasi is the first biosimil ... read article

Update on European application for Keytruda in combination with Pemetrexed and Carboplatin for first-line treatment of nonsquamous non-small cell lung cancer

Merck ( MSD ) has withdrawn its European application for Keytruda ( Pembrolizumab ) in combination with Pemetrexed and Carboplatin as a first-line treatment for metastatic nonsquamous non-small cell l ... read article

Apixaban associated with lower risk of stroke and lower rates of major bleeding compared to Warfarin

The findings from a real-world data analysis of the U.S. Humana database, in which treatment with Apixaban ( Eliquis ) was associated with a significantly lower risk of stroke / systemic embolism and ... read article

Positive results from PROSPER trial of Enzalutamide in patients with non-metastatic castration-resistant prostate cancer

The phase 3 PROSPER trial evaluating Enzalutamide ( Xtandi ) plus androgen deprivation therapy ( ADT ) versus ADT alone in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CR ... read article

The combination of Sacubitril and Valsartan protects against cardiac rupture and improves survival after acute myocardial infarction in murine model

A study examined the effects of LCZ696 ( Sacubitril and Valsartan; Entresto ) on acute experimental myocardial infarction ( MI ) in mice and whether it has cardioprotective effects beyond renin-angiot ... read article

Nivolumab in glioblastoma multiforme, CheckMate -143 did not meet its primary endpoint of improved overall survival

CheckMate -143, a randomized phase 3 clinical trial evaluating the efficacy and safety of Nivolumab ( Opdivo ) in patients with first recurrence of glioblastoma multiforme ( GBM ), did not meet its pr ... read article

Androgen receptor-inhibitors: Enzalutamide improves metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer

The phase 3 PROSPER trial evaluating Enzalutamide ( Xtandi ) plus androgen deprivation therapy ( ADT ) versus ADT alone in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CR ... read article

Parkinson's disease: Safinamide improves motor function, overall clinical status and health-related quality of life

Safinamide ( Xadago ) is an orally active, selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic ( glutamatergic ) properties. In the European Union, Safi ... read article

Nivolumab in glioblastoma multiforme, CheckMate -143 did not meet its primary endpoint of improved overall survival

CheckMate -143, a randomized phase 3 clinical trial evaluating the efficacy and safety of Nivolumab ( Opdivo ) in patients with first recurrence of glioblastoma multiforme ( GBM ), did not meet its pr ... read article

Advanced BRCA-related breast cancer: Olaparib, a PARP inhibitor, is superior to chemotherapy

During the American Society of Clinical Oncology ( ASCO ) Annual Meeting, the results of the phase III OlympiAD trial demonstrating for the first time that Olaparib ( Lynparza ) is superior to chemoth ... read article

Relapsing multiple sclerosis: oral Ozanimod has shown improvements compared to Interferon beta-1a for the primary endpoint of annualized relapse rate

SUNBEAM trial, evaluating the efficacy and safety of O)zanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis ( RMS ), met the primar ... read article

Actemra is the first FDA-approved treatment for adults with giant cell arteritis

The U.S. Food and Drug Administration ( FDA ) has approved Actemra [ European Union: RoActemra ] ( Tocilizumab ) subcutaneous injection for the treatment of giant cell arteritis ( GCA ), a chronic and ... read article